» Articles » PMID: 21669378

Using Health State Utility Values from the General Population to Approximate Baselines in Decision Analytic Models when Condition-specific Data Are Not Available

Overview
Journal Value Health
Publisher Elsevier
Date 2011 Jun 15
PMID 21669378
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Decision analytic models in health care require baseline health-related quality of life data to accurately assess the benefits of interventions. The use of inappropriate baselines such as assuming the value of perfect health (EQ-5D = 1) for not having a condition may overestimate the benefits of some treatment and thus distort policy decisions informed by cost per quality adjusted life years thresholds.

Objective: The primary objective was to determine if data from the general population are appropriate for baseline health state utility values (HSUVs) when condition specific data are not available.

Methods: Data from four consecutive Health Surveys for England were pooled. Self-reported health status and EQ-5D data were extracted and used to generate mean HSUVs for cohorts with or without prevalent health conditions. These were compared with mean HSUVs from all respondents irrespective of health status.

Results: More than 45% of respondents (n = 41,174) reported at least one condition and almost 20% reported at least two. Our results suggest that data from the general population could be used to approximate baseline HSUVs in some analyses, but not all. In particular, HSUVs from the general population would not be an appropriate baseline for cohorts who have just one condition. In these instances, if condition specific data are not available, data from respondents who report they do not have any prevalent health condition may be more appropriate. Exploratory analyses suggest the decrement on health-related quality of life may not be constant across ages for all conditions and these relationships may be condition specific. Additional research is required to validate our findings.

Citing Articles

The Cost-Effectiveness of Sentinel Lymph Node Mapping in High-Risk Endometrial Cancer.

Burg L, Vermeulen R, Bekkers R, Kruitwagen R, Zusterzeel P Cancers (Basel). 2025; 16(24.

PMID: 39766139 PMC: 11674379. DOI: 10.3390/cancers16244240.


Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness.

Mandrik O, Thomas C, Akpan E, Catto J, Chilcott J Pharmacoeconomics. 2025; .

PMID: 39753833 DOI: 10.1007/s40273-024-01463-y.


Baseline Characteristics in the Remote Diet Intervention to REduce long-COVID Symptoms Trial (ReDIRECT).

Haag L, Richardson J, Haig C, Cunningham Y, Fraser H, Brosnahan N NIHR Open Res. 2024; 4:7.

PMID: 39145102 PMC: 11320183. DOI: 10.3310/nihropenres.13522.1.


Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.

Rey-Ares L, Averin A, Mac Mullen M, Hariharan D, Atwood M, Carballo C Infect Dis Ther. 2024; 13(6):1235-1251.

PMID: 38700655 PMC: 11128425. DOI: 10.1007/s40121-024-00972-9.


Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis.

Horner D, Davis S, Pandor A, Shulver H, Goodacre S, Hind D Health Technol Assess. 2024; 28(20):1-166.

PMID: 38634415 PMC: 11056814. DOI: 10.3310/AWTW6200.